metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
breast cancer - triple negative breast cancer - triple negative
versus Standard of Care (SoC)
	durvalumab alone
	Saphir02 Breast-Immuno, 2021 Nat Med 2021; 27:250-255-. NCT02299999	RCT	breast cancer - triple negative	durvalumab	chemotherapy	patients with human epidermal growth factor receptor type 2 (Her2)-negative metastatic breast cancer whose disease did not progress after initial chemotherapy (maintenance chemotherapy).	131 / 68	some concern	inconclusive	inconclusive 40 % increase in progression or deaths (PFS) (PE) Maintenance chemotherapy was more effective than durvalumab in patients with hormone receptor-positive and Her2-negative disease.